China (Mainland)
Premiumsupplier
Sorafenib CAS NO.284461-73-0
- FOB Price: USD: 7.00-7.00 /Gram Get Latest Price
- Min.Order: 100 Gram
- Payment Terms: L/C,T/T,Other
- Available Specifications:
1(10-50)Gram
- Product Details
Keywords
- 284461-73-0
- Sorafenib
- 98% Sorafenib
Quick Details
- ProName: Sorafenib
- CasNo: 284461-73-0
- Molecular Formula: C21H16ClF3N4O3
- Appearance: C21H16ClF3N4O3
- Application: Used for research and industrial manuf...
- DeliveryTime: Within7-10 days after receipt of your ...
- PackAge: As customer request
- Port: Qingdao,China
- ProductionCapacity: 100 Kilogram/Month
- Purity: 98% min
- Storage: 3 years -20°C powder; 2 years -80°C in...
- Transportation: Common products:Sea/Air/Courier ...
- LimitNum: 100 Gram
Superiority
Lorcaserin(856681-05-5)is an orally administered agent and a selective 5-HT2C receptor agonist for the treatment of obesity. It had been approved for marketing in US by FDA on 27 June in 2012. In clinical studies, lorcaserin has demonstrated efficacy in obese and overweight populations by promoting weight loss and improving metabolic parameters, and it is well tolerated.
Details
| Molecular Weight | 464.83 |
| Formula | C21H16ClF3N4O3 |
| CAS Number | 284461-73-0 |
| Solubility | DMSO: 63 mg/mL warmed (135.53 mM) |
| Storage |
3 years -20°C powder; 2 years -80°C in solvent; |
| Remark | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ℃ for several month. |
Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.
